+303.3%
ZETA vs GSK
+58.3%
+245.0%
-70.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | -0.1% | -2.1% | -2.2% |
| 7D | +10.6% | -1.3% | +11.9% | +10.7% |
| 30D | +12.7% | +2.7% | +10.0% | +12.4% |
| 3M | +23.4% | +2.7% | +20.7% | +23.1% |
| 6M | +108.6% | +3.3% | +105.2% | +107.5% |
| YTD | +76.2% | +6.5% | +69.7% | +73.5% |
| 1Y | +94.4% | +10.7% | +83.8% | +90.4% |
| 3Y | +325.3% | +64.4% | +260.9% | +291.2% |
| 5Y | +292.2% | +46.7% | +245.5% | +260.2% |
| All | +303.3% | +58.3% | +245.0% | +279.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling